A healthier you, made simple and affordable
Our CPG doctors prescribe the most effective and appropriate medication for our patients. We provide all options from GLP-1’s to generic medication. Read over what medications we prescribe below!
Wegovy® / Ozempic®
Active ingredient: Semaglutide
Semaglutide is a GLP-1 agonist created for Type 2 Diabetes and FDA-approved in 2019. It was approved for the indication of weight loss as Wegovy® in June 2021.
GLP-1 works to increase insulin levels by activating cells in the pancreas. It also triggers hormone release to delay the emptying of the stomach, sometimes causing nausea.
When used alongside robust lifestyle management (200 min exercise/week, nutri-system diet, bimonthly nutritionist visits) patients observed 10-14% weight loss, maintained over 2 years (STEP3 Trial, Novo Nordisk).1
Nausea (44%); vomiting (25%); diarrhea/GI distress (30%)
History of thyroid C-cell tumors; pregnant; breastfeeding; trying to conceive; history of anorexia/bulimia
Both GLP-1 and GIP receptors work to decrease the rate your stomach empties-keeping you full for longer! They also work to decrease your appetite and cravings.
The SURMOUNT-1 trial showed expected weight loss of 22.5%. Additional trials have shown this medication is twice as effective as Semaglutide 1.0mg.1
Nausea (44%); vomiting (25%); diarrhea/GI distress (30%)
Chronic malabsorption; pregnancy; cholestasis/history of gallbladder disease; pancreatitis; family history of thyroid cancer; thyroid disorders
Mounjaro® / Zepbound®
Active ingredient: Tirzepatide
Tirzepatide is the newest form of weight loss medication. It was recently approved for Type 2 diabetes, and works through both the GLP-1 receptor and GIP receptors..
Saxenda® / Victoza®
Active ingredient: Liraglutide
Liraglutide is a GLP-1 agonist medication, very similar to Semaglutide. It was initially developed as a medication for Type 2 Diabetes, but found to also help patients with weight loss.
By activating GLP-1 receptors, this medication works to slow the rate at which your stomach empties, and to send signals to your brain to decrease appetite.
The SCALE Trial showed patients can lose 6.2% over 52 weeks (CI 7.5 to 4.6%).1
Nausea (44%); vomiting (25%); diarrhea/GI distress (30%)
Pancreatitis gallstones; family history of thyroid cancer; thyroid disorders